BioSpace News Archive

Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced financial results for the second quarter ended June 30, 2021, as well as business highlights.

Inari Medical, Inc. a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, reported financial results for its second quarter ended June 30, 2021.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Leading physicians and researchers will present results from 16 clinical trials focused on vascular interventional technology and treatment solutions on Tuesday, October 5, and Wednesday, October 6, at the 19th annual VIVA conference at Wynn Las Vegas.

The regenerative medicine company Seraxis today announces that Shelley Hartman , Jerry Baty , and Min-Jung Choi are appointed to its Board of Directors.

NANO-X IMAGING LTD, an innovative medical imaging technology company, announced results for the second quarter ended June 30, 2021 and provided a business update.

CASI Pharmaceuticals, Inc. today announced the Company will host a conference call reviewing the second quarter highlights at 8:00 a.m. ET on Thursday , August 12 th , 2021.

IMV Inc. today announced the final topline results of the DeCidE1 Phase 2 clinical trial evaluating maveropepimut-S (MVP-S, formerly known as DPX-Survivac) in subjects with advanced recurrent ovarian cancer.

BioLargo, Inc. will host an investor webcast and conference call on Wednesday August 17, 2021, at 8:00 am PST / 11:00 am EST, open to the public, to review the company’s financial results, discuss recent events, and conduct a question-and-answer session.

Immunovia AB received final regulatory approval to begin patient testing with the IMMray TM PanCan-d test, the first and only test on the market dedicated to the early detection of pancreatic cancer.